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Abstract
Background: All children and adolescents between 1 and 19 years of age in The Netherlands received a single
meningococcal serogroup C conjugate (MenCC) vaccine in 2002. During follow-up 4–5 years later, the persistence of MenC
polysaccharide-specific IgG was found to be dependent on age of vaccination with higher IgG levels in the oldest
immunized age categories.
Methods and Findings: Two cross-sectional population-based serum banks, collected in 1995/1996 and in 2006/2007, were
used for this study. We measured MenC polysaccharide-specific IgM, the IgG1 and IgG2 subclasses and determined the
avidity of the IgG antibodies. We report that the age-related persistence of IgG after immunization with the MenCC vaccine
seemed to result from an increase of IgG2 levels with age, while IgG1 levels remained stable throughout the different age-
cohorts. Furthermore, an age-related increase in IgM levels was observed, correlating with the persistence of IgG antibodies
with age. It is noteworthy that the increase in IgG2 correlated with a reduced IgG-avidity with age.
Conclusion: These date indicate that the classical characteristics of a T-cell-dependent antibody response as elicited by
protein based vaccines might not be completely applicable when conjugate vaccines are administered to older children and
adolescents up to 18 years of age. The response elicited by the MenCC vaccine seemed to be more a mixture of both T cell
dependent and T cell independent responses in terms of humoral immunological characteristics.
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Introduction
Conjugate vaccines to prevent bacterial meningitis and sepsis
caused by pathogens like Haemophilus influenzae type B (Hib),
Streptococcus pneumoniae and Neisseria meningitidis have proven to lead
to a tremendous decrease in incidence of these diseases when
introduced in national immunization programs (NIPs) [1]. Because
of the high incidence of diseases in early childhood, particularly in
the first 2–3 years of life, vaccination usually needs to start within
the first months after birth. However, in contrast to Hib and
pneumococcal disease, the incidence of invasive meningococcal
infections also shows a second peak in the disease rate among
adolescents in the ages 14–19 years [2,3]. Therefore together with
the implementation of meningococcal serogroup C (MenC)
immunization in NIPs, many countries also conducted so called
catch-up campaigns for children and adolescents up to the age of
24 years [2,4,5]. In the Netherlands, a single MenC conjugate
(MenCC) immunization (NeisVac-C, Baxter, USA) was imple-
mented in the National Immunization Programme at 14 months
of age in 2002 for all newborns and a catch-up campaign was
simultaneously initiated targeting all children and adolescents from
1 year up to the age of 18 (vaccine coverage 94%). This approach
resulted in an immediate and dramatic decline in MenC disease in
all age categories with only few cases in unvaccinated individuals
each year without any vaccine failures [6]. This decrease was due
to herd effects caused by reduced carriage in the immunized
adolescents, who previously had the highest carriage rates [7].
Several serosurveillance studies in a number of countries have
been conducted to monitor the persistence of MenC polysaccha-
ride (PS)-specific IgG and serum bactericidal antibodies at
different ages after introduction of a MenC conjugate vaccine
[8–11]. All studies revealed that sustainment of (bactericidal)
antibodies after a single MenC conjugate (MenCC) immunization
increased with the age at which the vaccine was administered.
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This is suggested to be due to immune maturation with age and
also natural priming with meningococcus during childhood. In the
Netherlands, up till 95% of young adults at 22 years who had
received a single MenCC vaccine 4–5 years earlier, still had
protective antibody levels present [8]. Furthermore, we recently
showed that not only antibodies directed towards the polysaccha-
ride gradually increase with age, but also antibodies directed
against the carrier protein increased in a similar age-related
manner [8]. Unfortunately, data on the development and
persistence of vaccine-induced antibodies at increasing age during
childhood and adolescence are scarce, and the interval between 2
and 18 years is seldom studied, apart from the rare opportunities
given during a catch-up campaign.
In the present study we investigated whether the immune
response elicited by the single MenCC vaccine changed with age,
not only in terms of height of the antibody levels during childhood
and adolescence, but also in terms of type and properties of
antibodies induced. We therefore compared two large and unique
cross-sectional serosurveillance studies which were conducted in
the pre- and post introduction of MenCC vaccination era in the
Netherlands [12,13]. In these cross-sectional cohort studies of
persons aged between 0 and 80 years of age we measured MenC-
specific IgM levels, as well as the IgG subclass distribution and
avidity.
Materials and Methods
The two cross-sectional serosurveillance studies have been
previously described [12,13]. The pre-MenC introduction ser-
osurveillance study was approved by the medical ethical
committee of TNO Prevention and Health in Leiden and
performed in 1995/1996. The post-MenC introduction serosur-
veillance study was approved by the medical ethics testing
committee of the foundation of therapeutic evaluation of
medicines (METC-STEG) in Almere (clinical trial number:
ISRCTN 20164309) and performed in 2006/2007. All partici-
pants or parents/guardians of minors involved in both studies
provided written informed consent.
Study samples
The seroprevalences and levels of MenC PS-specific IgG and
bactericidal antibodies pre- and post-introduction of the MenCC
vaccine in the Netherlands have been described previously [8]. In
the present study, MenC PS-specific IgM (n = 1096) in different
age-cohorts (0–79 years of age) was determined in the same serum
sample set from the post-MenC introduction era of which serum
bactericidal (SBA) prevalence (n = 1220) was previously described
[8]. Furthermore, all serum samples from this subset that
contained $0.25 mg/ml MenC-specific IgG were examined for
their meningococcal serogroup A and C-specific IgG1 and IgG2
subclass distribution (n = 654) and meningococcal serogroup C PS-
specific IgG avidity (n = 649). In addition, a set of age-matched
serum samples were randomly selected from the pre-MenC
introduction serosurveillance study to measure the MenC PS-
specific IgM levels in different cohorts (ages 0–79 years) (n= 323).
Detection of MenA and C-specific IgG subclasses and
MenC PS-specific IgM
Meningococcal serogroup A and C-specific IgG1, IgG2 and
MenC PS-specific IgM antibodies were quantified using a
fluorescent-bead-based multiplex immunoassay (MIA) as pub-
lished before [14,15]. Standardized reference serum CDC 1992
was used in this assay (NIBSC, Potters Bar, UK). Samples were
analyzed using a Bio-Plex 200 system in combination with the Bio-
Plex Manager software, version 4.1.1 (Bio-Rad Laboratories,
Hercules, CA). For each analyte, median fluorescent intensity was
converted to mg/ml by interpolation from the 5-parameter logistic
standard curve. The lower limit of quantitation was assigned at
0.01 mg/ml for statistical purposes.
Analysis of MenC-specific IgG serum avidity
To determine antibody avidity of MenC-specific IgG antibodies
a modification of the MIA for measurement of MenC-specific IgG
was used, as previously described [16]. Briefly, serum samples with
an IgG concentration of $0.25 mg/ml were adjusted to an
antibody concentration of 25 ng/ml. Ammonium thiocyanate,
0.5M (NH4SCN; Sigma-Aldrich, St. Louis, MO) was used to
dissociate low-avidity antigen-antibody binding. Samples were
measured with the Bio-Plex 200 system as described above. The
avidity index (AI) is the percentage of antibodies that remains
bound to the MenC PS-conjugated beads after treatment with
NH4SCN and is calculated as follows: AI = (amount of IgG with
NH4SCN)/(amount of IgG with PBS)6100. Sera per cohort were
subdivided in high, intermediate and low IgG avidity sera, based
on the following AI: high, 100–66%; intermediate, 66–33%; and
low, 0–33%.
Statistical analysis
Analysis of the data was performed using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego, CA,
USA) and SAS 9.1.3 (SAS Institute Inc. Cary, NC, USA).
Differences between groups were determined using the non-
parametric Mann-Whitney test and correlations were determined
using the non-parametric Spearman test. A P-value of 0.05 was
considered statistically significant.
Results
Meningococcal serogroup C-specific IgM
Previously, we described in a study on adult MenCC
immunization, that higher MenC PS-specific IgM levels were
present in adults who had received a single MenCC vaccine 5
years earlier as compared to individuals who had not received a
MenCC immunization before [16]. In the present study we
determined MenC PS-specific IgM levels 5 years after the
national MenCC catch-up campaign in different age-cohorts
and compared these to levels of IgM in non-immunized aged-
matched individuals from the pre-MenC introduction era
(Figure 1). A significantly higher level of IgM is observed in
the age-cohort to whom the routine infant immunization at 14
months of age is offered as compared to the pre-MenC
introduction survey samples (P,0.001). However, in the cohorts
of children 2 and 3–4 years of age there was already no
difference in IgM antibody levels between the pre-MenC and
post-MenC group. In line with the previously described IgG
levels [8], also a clear age-related increase in persisting IgM
levels was observed in samples from the post-MenC introduction
survey. IgM-levels in individuals aged 11 to 21 years, that had
been immunized 4–5 years earlier, were significantly higher
than in the pre-MenC immunization era (P , 0.001), although
in general still at low concentrations (Figure 1). These higher
levels of MenC PS-specific IgM significantly correlated with the
higher levels of IgG within the immunized age-cohorts
(r = 0.7571, cohorts 15 months to 21 years, Table 1). Levels of
IgM in the non-immunized age-cohorts (above 25 years of age)
were not significantly different between pre- and post-MenC
introduction surveys (Figure 1).
Age-Related MenC-Specific Antibody Responses
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Meningococcal serogroup C polysaccharide-specific IgG
avidity
To see whether the previously observed increase in IgG with
age of immunization was linked with increased avidity, which is
proposed to be a hallmark of immune memory [17], we
determined avidity in various age-cohorts. In age-cohorts who
had recently received a single MenCC immunization at 14 months
of age during the cohort study in 2006/7, an increase in the
fraction of sera with relatively high avidity antibodies was observed
(Figure 2). In the cohort 15–23 months, 12% of the sera revealed a
relatively high avidity index (AI), which increased up to 56% of the
sera at 3–4 years of age. Interestingly, in the catch-up campaign
age-cohorts of 2002, the fraction of individuals that showed a
relatively high AI gradually decreased with age. In the youngest
catch up cohort, (7–8 years of age at time of blood sampling, and
3–4 years at the time of vaccination), 31% of persons revealed a
relatively high AI which decreased with age to 14% in the oldest
immunized age-cohorts (19–21 years of age at time of blood
sampling and 15–17/8 at the time of vaccination) (Figure 2). The
percentage of sera with relatively intermediate AI remained rather
constant throughout the different vaccinated cohorts. As a
consequence of above, the percentage of sera with low AI
Figure 1. Meningococcal serogroup C PS-specific IgM levels. Levels of IgM in the pre-MenC introduction era are shown in grey bars, the post-
MenC introduction era are shown in black bars. Routine immunization is offered in the post-MenC introduction era at 14 months of age and children
and adolescents between 5–21 years of age received a single immunization 4–5 years earlier. Error bars indicate 95% confidence intervals. Age at
bloodsampling is indicated in years or as stated otherwise (mo = age in months).
doi:10.1371/journal.pone.0023497.g001
Table 1. Correlations between levels of IgG, IgG1 or IgG2 and percentages of low or high AI per cohort.
IgM IgG1 IgG2 % Low AI % High AI
r p n r p n r p n r p n r p n
IgG (cohorts
15 months – 79 year)
0.7571 0.0010 15 0.0750 0.7905 15 0.6964 0.0039 15 0.5571 0.0351 15 20.7643 0.0009 15
IgG (cohorts
15 months – 21 year)
0.6818 0.0208 11 0.2273 0.5015 11 0.8636 0.0006 11 0.8000 0.0021 11 20.9727 ,.0001 11
IgG1 (cohorts
15 months – 79 year)
0.2893 0.2957 15 ND ND NA 20.5964 0.0189 15 20.6393 0.0103 15 0.3679 0.1773 15
IgG1 (cohorts
15 months – 21 year)
20.0909 0.7904 11 ND ND NA 20.1455 0.6696 11 20.1182 0.7293 11 20.1909 0.5739 11
IgG2 (cohorts
15 months – 79 year)
0.2536 0.3618 15 ND ND NA ND ND NA 0.8786 ,.0001 15 20.8179 0.0002 15
IgG2 (cohorts
15 months – 21 year)
0.9364 ,.0001 11 ND ND NA ND ND NA 0.8727 0.0005 11 20.8455 0.0010 11
Spearman’s rank correlation coefficient (r) with the p values (p) and the number of cohorts tested for each association (n).
ND, not done; NA, not applicable.
doi:10.1371/journal.pone.0023497.t001
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increased with age. The rise in the percentage of individuals with a
relatively low AI positively correlates with the rise of IgG levels
with age in the immunized age-cohorts (r = 0.8000, Table 1). A
negative correlation was found between the percentage of
individuals with a relatively high AI and total MenC PS-specific
IgG levels in all age-cohorts (Table 1). In non-immunized
individuals (above 25 years of age), more than half of all
individuals (59%) revealed a relatively low AI.
Meningococcal serogroup A and C IgG subclass
distribution
We measured the MenA PS-specific IgG1 and IgG2 levels and
IgG1/IgG2 ratio’s, which were expected to be elicited by natural
exposure or cross-reactivity and not to vaccination [18], and
compared these to the MenC PS-specific IgG1 and IgG2 levels
and IgG1/IgG2 ratio’s from vaccinated cohorts and older non-
immunized cohorts in the post-introduction era of the MenCC
vaccine (Figure 3). The MenA PS-specific IgG1/IgG2 ratios
showed the clear age-specific pattern which is to be expected for
TI antigens: an apparent IgG1 response is observed during
childhood, illustrated by an on average IgG1/IgG2 ratio of 6 in
the cohorts aged 0–6 years, which gradually shifts via a similar
IgG1 and IgG2 level in adolescents (average ratio of 1, between 7
and 18 years of age) towards a clear IgG2 response in adults
(average ratio of 0.20, above 25 years of age) (Figure 3). The
MenC PS-specific IgG1/IgG2 ratios showed a somewhat different
picture with age: a significantly higher IgG1/IgG2 ratio (average
ratio of 31) is observed in the youngest cohorts (0–6 years)
compared to the MenA ratio, which shifts to a clear IgG2 response
in the non-immunized cohorts (.25 years of age) with an average
IgG1/IgG2 ratio of 0.25 (Figure 3). However, compared to the
IgG1/IgG2 ratio of MenA-specific antibodies, higher IgG1/IgG2
ratios in the cohorts between 7 and 21 years of age (average ratio
of 6) were observed for MenC. In addition, an inverse correlation
between the levels of MenC PS-specific IgG1 and IgG2 within all
cohorts (15 months to 79 years of age) was observed (Table 1).
However, this correlation does not exist when only the levels of
IgG1 and IgG2 in the immunized cohorts were compared
(Table 1).
Correlation between IgG levels, IgG subclass distribution
and overall IgG avidity
Concentrations of IgG, IgG1, IgG2 and the percentage of
persons with a relatively low AI in each cohort are depicted in
figure 4A. Levels of IgG1 remain at a relative constant level
throughout the different immunized cohorts, while the levels of
IgG2 rise with the age at immunization (Figure 4A–C). The age-
related increase in the prevalence of MenC PS-specific IgG is,
besides the correlation with IgM, significantly correlated with the
levels of MenC PS-specific IgG2 in all cohorts (r = 0.6964). This is
further emphasized by an even stronger correlation (r = 0.8636)
between the levels of IgG with the levels of IgG2 in the immunized
cohorts only (cohorts between 15 months and 21 years of age),
while there was no significant correlation between the levels of IgG
and IgG1 within these immunized cohorts (Figure 4B–C &
Table 1). No correlation between levels of IgG, IgG1, IgG2 and
serum IgG avidity was found within the non-immunized groups
above 25 years of age.
We also found a positive correlation between the increase in
IgG2 levels with age and the age-related increase in the percentage
of individuals with a relatively low AI in the MenCC immunized
cohorts (11 cohorts, age 15 months –21 years), while an inverse
correlation existed between the percentage of individuals with low
AI and IgG1 levels with age (Figure 4D–E, Table 1). On the other
hand, an inverse correlation between the percentage of individuals
with a relatively high AI and the increase in IgG2 levels with age
was found (Table 1). However, this inverse correlation does not
exist when comparing the percentage of individuals with a
Figure 2. Meningococcal serogroup A and C PS-specific IgG1/IgG2 ratios (grey and black bars, respectively). An IgG1/IgG2 ratio of .1
indicates a higher level of IgG1; an IgG1/IgG2 ratio of ,1 indicates a higher level of IgG2. MenCC immunization is offered at 14 months of age and
children and adolescents between 5–21 years of age received a single immunization 4–5 years earlier. Error bars indicate 95% confidence intervals.
Age at bloodsampling is indicated in years or as stated otherwise (mo = age in months).
doi:10.1371/journal.pone.0023497.g002
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relatively low AI with the levels of IgG1 within the immunized
cohorts only, whereas the positive correlation with IgG2 continues
to exist within these cohorts (Table 1). This positive correlation
between low AI and IgG2 was even further illustrated when all
sera with an IgG1/IgG2 ratio ,1 were compared to all sera with
an IgG1/IgG2 ratio .1. The sera with an IgG1/IgG2 ratio ,1
showed a significantly lower AI than the sera with an IgG1/IgG2
ratio .1 (P,0.0001) (Figure 4f). We can therefore conclude that
the avidity of MenC PS-specific IgG is mainly determined by IgG1
antibodies. The increase in the levels of IgG2 to MenC with age
thus leads to a reduction in the avidity with age.
Discussion
In the present study we have investigated various aspects of the
humoral immune response elicited by immunization with a single
MenCC vaccine at different ages 4–5 years after MenCC
vaccination and compared these with historic age-matched
controls without MenCC vaccination. We found that the age-
related levels of MenC PS-specific IgG following vaccination
resulted from an increase in IgG2 antibodies with age, while IgG1
remained at a similar level throughout the different age-cohorts.
Furthermore, this increase in IgG2 with age was also related to a
reduced IgG avidity with age. Besides IgG, also an age-related
increase of MenC PS-specific IgM levels was observed, which
significantly correlated with the increased levels of total IgG and
IgG2 antibodies with age.
Data about the effects of conjugate immunization at older ages
compared with infant vaccinations are scarce and are primarily
derived from the H. influenza type b conjugate vaccine [17,19,20].
Our present data from MenCC routine immunized children at 14
months of age show T cell dependent (TD) response character-
istics: low levels of IgM, a clear induction of the IgG1 subclass and
an increase in avidity of IgG antibodies in the years following
immunization, as was previously also seen for other conjugate
vaccines [17,21]. However, our data show that as vaccination
occurs at a later age, humoral responses seem to shift towards a T
cell independent (TI) response: induction of IgM, increasing
levels of IgG2 and a lower avidity of IgG antibodies. Remarkably,
the immune response described was measured in a population
that was immunized with a single MenCC vaccination 4–5 years
earlier. However, a characteristic TI response would have been
thought to be transient, with IgG antibody responses that would
have declined to low levels within a few years and no induction of
immunological memory. Clearly, this is not the case, as memory
B cell responses have been demonstrated previously after booster
immunization at infant, adolescent and adult ages [16,22–24].
Indeed, if we compare the MenC PS-specific IgG1/IgG2 ratios to
the naturally elicited MenA PS subclass ratios in the MenCC
immunized cohorts, the major subclass induced by vaccination
was found to be IgG1, which should be indicative for a TD
response [25]. However, levels of IgG2 increased with age of
vaccination and accounted for the increasing prevalence of
overall IgG with age. Moreover, we found a reduced IgG avidity
with age, while an increase in avidity is considered to be one the
main features of a TD response. Low-avidity antibodies
predominate during the acute-phase of an immune response,
whereas high-avidity antibodies are selected and produced later
and thus would have been expected in the years following
immunization [26]. In view of this rationale, the presence of low-
avidity antibodies was unexpected but might be explained by the
higher levels of IgG2 with age, which is in concordance with
other studies [27,28]. Goldblatt et al. found that following
MenCC vaccination in adults the already relative high avidity of
antibodies failed to mature further in the subsequent 6 months
[29]. The index even seemed to decrease slightly in this period
which could be in line with our observation of decreasing avidity
in the young adults 5 years following their single vaccination.
Figure 3. Avidity of Meningococcal serogroup C PS-specific IgG. Sera with an avidity indices (AI) of 0–33 are indicated as low AI (in black),
sera with an AI of 34–66 are determined to be of intermediate AI (in white) and sera with an AI of 67–100 are assigned to be of high AI (in grey). Age
at bloodsampling is indicated in years or as stated otherwise (mo = age in months).
doi:10.1371/journal.pone.0023497.g003
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Figure 4. Correlation between levels of Meningococcal serogroup C PS-specific IgG, IgG1, IgG2 and IgG avidity within immunized
or non-immunized cohorts in the post-immunization era. A) Concentrations of IgG, IgG1, IgG2 and the percentage of persons with a relatively
low AI in each cohort. B) Correlation between IgG1 and IgG in the 11 immunized cohorts (15 months to 21 years of age, filled triangles) or in the 4
non-immunized cohorts (22 to 79 years of age, open triangles). C) Correlation between IgG2 and IgG in the 11 immunized cohorts (15 months to 21
years of age, filled circles) or in the 4 non-immunized cohorts (22 to 79 years of age, open circles). D) Correlation between IgG1 and the percentage of
individuals with low AI in the 11 immunized cohorts (15 months to 21 years of age, filled triangles) or in the 4 non-immunized cohorts (22 to 79 years
of age, open triangles). E) Correlation between IgG2 and the percentage of individuals with low AI in the 11 immunized cohorts (15 months to 21
years of age, filled triangles) or in the 4 non-immunized cohorts (22 to 79 years of age, open triangles). F) Comparison of the AI’s of sera with an IgG1/
IgG2 ratio .1 and an IgG1/IgG2 ratio ,1. * P,0.0001.
doi:10.1371/journal.pone.0023497.g004
Age-Related MenC-Specific Antibody Responses
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Interestingly, although the antibodies are of low avidity, the
amount of antibodies seems to play the major role with respect to
protection, since the total levels of IgG correlate well with
bactericidal antibodies [8].
Although the increase in levels of IgM observed in the
adolescent cohorts may not be of clinical relevance, due to their
quite low levels, they do suggest that either a prolonged immune
response is initiated or persistent antigen presentation might occur
[30]. However, because IgM is considered to be a ‘‘natural
antibody’’ [31], the possibility that IgM is elicited by cross-reactive
carbohydrates should not be ruled out. This probably might also
explain why there are no differences between pre- and post-
immunization era levels in the non-immunized individuals, which
is in contrast with the IgG levels [8].
Previously, it has been reported that the increased antibody
sustainment of MenC-specific antibodies could be caused by
natural priming before immunization, immune maturation or
possible circulation of the bacterium among the population
[10,32]. Currently, the circulation of MenC in the Netherlands
is expected to be very low, reflected by a low disease incidence in
non-immunized persons and carriage studies in other countries
which have implemented MenCC vacciantion have provided
evidence for reduced nasopharyngeal carriage [7]. It is therefore
not to be expected that the increased antibody levels observed after
introduction of the vaccine are caused by natural exposure to the
MenC bacterium. It can of course not be ruled out that other
commensal bacteria may cause cross-reactivity [33]. However, we
showed earlier that antibodies towards to the carrier protein,
tetanus toxoı¨d, are also maintained in an age-related manner,
which makes cross-reactivity less plausible [8]. Sustainment of
antibody levels is an active process dependent on both the
turnover and synthesis of antibodies [34]. Studies in mice have
shown that continuous production of antibodies is dependent on
the presence of (persisting) antigen [35,36]. Whether this is the
case when tetanus and MenC PS are administered in a conjugated
form is unknown and will be very difficult to demonstrate in
humans. However, our current data on persistence of IgM and
IgG2 lead to the suggestion that not only maturation and priming
of the immune system are implicated in the response towards
conjugate vaccines.
As indicated above, the working mechanism of polysaccharide-
conjugate vaccines still cannot unequivocally be classified as TD. It
has been described that marginal zone B cells play a prominent
role in the responses to non-conjugated polysaccharides [37]. This
may explain why in infants under 2 years of age immune responses
are impaired, because the marginal zone matures around the age
of 18 to 24 months [38,39]. Whether this subset of B cells is also
involved in the immune response towards conjugate vaccines is
unknown. The induction of immunological memory strongly
indicates that follicular B cells are involved and that germinal
centres are formed during the primary immune response.
However, as Pollard and colleagues describe [3], this would result
in a humoral response which is characterized by IgG1, IgG3 and
antibodies of high avidity, while we observe in our present study
increased levels of IgM, IgG2 and moderate to low avidity.
Unfortunately, we were unable to measure the IgG1/IgG2
subclass ratios and avidity in the pre-immunization cohort, since
MenC PS-specific antibody levels were very low [8]. Therefore, we
cannot exclude that pre-existing MenC IgG levels might have
been of influence also [40]. However, the MenA PS-specific
antibodies present in adolescent age-groups indicate an equal
IgG1 to IgG2 ratio. Therefore, our data may suggest that the
immune response towards conjugate vaccines may be comparable
but probably not completely identical to the response induced by
conventional protein antigens, which involves the subset of
follicular B cells, but that perhaps also the ‘‘classical’’ PS-specific
subset of marginal zone B cells is involved. Naturally primed
memory B cells may possibly participate in this response, since it is
likely that exposure to PS during nasopharyngeal carriage may
prime B cells, as the PS on the surface of the bacterium may be
seen by the immune system as a molecule conjugated to outer-
membrane proteins [29].
In conclusion, immunization with the meningococcal serogroup
C conjugate vaccine at increasing infant or adolescent age results
in increased persistence of IgM and IgG2 and is correlated with
the persistence of IgG and reduced IgG avidity. The response to
conjugate vaccines at ages above infancy does not seem to be a
fully conventional TD response, because it displays characteristics
of both TD and TI responses. Further studies should aim at the
molecular analysis of B cells and T cells involved in the responses
towards conjugate vaccines, which can provide evidence for the
nature of cells that are being activated by conjugate vaccines in
infants, adolescents and adults.
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